Vilazodone Hydrochloride Patent Expiration
Vilazodone Hydrochloride is Used for treating major depressive disorder (MDD). It was first introduced by Abbvie Inc
Vilazodone Hydrochloride Patents
Given below is the list of patents protecting Vilazodone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Viibryd | US5532241 | Piperidines and piperazines |
Sep 29, 2014
(Expired) | Abbvie |
Viibryd | US7834020 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun 05, 2022
(Expired) | Abbvie |
Viibryd |
US7834020 (Pediatric) | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec 05, 2022
(Expired) | Abbvie |
Viibryd | US8193195 | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun 05, 2022
(Expired) | Abbvie |
Viibryd |
US8193195 (Pediatric) | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec 05, 2022
(Expired) | Abbvie |
Viibryd | US8236804 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun 05, 2022
(Expired) | Abbvie |
Viibryd |
US8236804 (Pediatric) | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec 05, 2022
(Expired) | Abbvie |
Viibryd | US8673921 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun 05, 2022
(Expired) | Abbvie |
Viibryd |
US8673921 (Pediatric) | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec 05, 2022
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vilazodone Hydrochloride's patents.
Latest Legal Activities on Vilazodone Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Vilazodone Hydrochloride.
Activity | Date | Patent Number |
---|---|---|
![]() | ||
Expire Patent Critical | 08 Jul, 2024 | US8193195(Litigated) |
Maintenance Fee Reminder Mailed Critical | 25 Mar, 2024 | US8236804(Litigated) |
Maintenance Fee Reminder Mailed Critical | 22 Jan, 2024 | US8193195(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 04 May, 2022 | US7834020(Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 01 Sep, 2021 | US8673921(Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jan, 2020 | US8236804(Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 21 Nov, 2019 | US8193195(Litigated) |
Request for Trial Denied Critical | 23 Jul, 2018 | US8673921(Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 03 May, 2018 | US7834020(Litigated) |
Petition Requesting Trial | 05 Jan, 2018 | US8673921(Litigated) |
Try Our Curated Drug Screens
Vilazodone Hydrochloride Generics
Several generic applications have been filed for Vilazodone Hydrochloride. The first generic version for Vilazodone Hydrochloride was by Teva Pharmaceuticals Usa and was approved on Sep 30, 2019. And the latest generic version is by Apotex Inc and was approved on Jul 7, 2023.
Given below is the list of companies who have filed for Vilazodone Hydrochloride generic.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG | tablet | Prescription | ORAL | AB | Apr 27, 2021 |
20MG | tablet | Prescription | ORAL | AB | Apr 27, 2021 |
40MG | tablet | Prescription | ORAL | AB | Apr 27, 2021 |
2. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Alembic.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20MG | tablet | Prescription | ORAL | AB | Jan 10, 2020 |
10MG | tablet | Prescription | ORAL | AB | Jan 10, 2020 |
40MG | tablet | Prescription | ORAL | AB | Jan 10, 2020 |
3. APOTEX
Apotex Inc has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Apotex.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG | tablet | Prescription | ORAL | AB | Jul 7, 2023 |
20MG | tablet | Prescription | ORAL | AB | Jul 7, 2023 |
40MG | tablet | Prescription | ORAL | AB | Jul 7, 2023 |
4. INVAGEN PHARMS
Invagen Pharmaceuticals Inc has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Invagen Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG | tablet | Prescription | ORAL | AB | Apr 7, 2021 |
40MG | tablet | Prescription | ORAL | AB | Apr 7, 2021 |
20MG | tablet | Prescription | ORAL | AB | Dec 6, 2022 |
5. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 3 different strengths of generic version for Vilazodone Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
20MG | tablet | Prescription | ORAL | AB | Sep 30, 2019 |
10MG | tablet | Prescription | ORAL | AB | Sep 30, 2019 |
40MG | tablet | Prescription | ORAL | AB | Sep 30, 2019 |